Ifosfamide in advanced/disseminated breast cancer

Oncology

Volumn 65, Issue SUPPL. 2, 2003, Pages 55-58

  Sorio, R ^a   Lombardi, D ^a   Spazzapan, S ^a   La Mura, N ^a   Tabaro, G ^a   Veronesi, A ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Breast cancer; Ifosfamide; Mesna; Urotoxicity

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PACLITAXEL;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; CHRONIC TUBULOINTERSTITIAL DAMAGE; CLINICAL TRIAL; CONFERENCE PAPER; DISSEMINATED CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LOW DRUG DOSE; MEDLINE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STANDARDIZATION; THROMBOCYTOPENIA; TOXICITY; TUBULAR DYSFUNCTION; UROTOXICITY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME; VINBLASTINE;

EID: 0242288535     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073360     Document Type: Conference Paper

References (36)

1. Boddy AV, Yule SM: Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000;38:291-304.
2. Ricotti L, Barzanti F, Tesei A, et al: Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. Ann Oncol 2000;11:587-594.
3. Hortobagyi G: Activity of ifosfamide in breast cancer. Semin Oncol 1992;19:36-42.
4. Overmoyer BA: Ifosfamide in the treatment of breast cancer. Semin Oncol 1996;23(suppl 6):38-41.
5. Boddy AV, Proctor M, Simminds D, et al: Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995;31:69-76.
6. Johnstone EC, Lind MJ, Griffin MJ, Boddy AV: Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemother Pharmacol 2000;46:433-441.
7. Michelotti A, Salvadori B, Donati S, et al: A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. Tumori 1997;83:826-828.
8. Bisagni G, Boni C, Manenti AL, et al: Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: Phase II study. Tumori 1998;84:659-661.
9. Walters RS, Holmes FA, Valero V, et al: Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol 1998;21:413-415.
10. Di Lauro V, Spazzapan S, Lombardi D, et al: Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil. Tumori 2001;87:27-29.
11. Gad-el-Mawla N: Use of ifosfamide in the management of breast cancer. Ann Oncol 1992;3:21-23.
12. Becher R, Hofeler H, Kloke O, et al: Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer. Oncology 1991;48:459-463.
13. Hoffmann W, Weidmann B, Migeod F, et al: Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. Cancer Chemother Pharmacol 1990;26(suppl):69-70.
14. Lind MJ, Gumbrell L, Cantwell BMJ, et al: The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer 1995;71:610-613.
15. Perez JE, Machiavelli M, Leone BA, et al: Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:461-466.
16. Manegold C, Worst P, Bickel J, et al: Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. Cancer Chemother Pharmacol 1990;26:S87-S90.
17. Millward MJ, Harris AL, Cantwell BMJ: Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer 1990;65:2421-2425.
18. Bitran JD, Samuels BL, Marsik S, et al: A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res 1995;1:185-188.
19. Leone BA, Vallejo CT, Romero AO, et al: Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2993-2999.
20. Buzdar AU, Legha SS, Tashima CK, et al: Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 1979;63:115-120.
21. Becher R, Kloke O, Hayungs J, et al: Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 1996;23(suppl 7):28-33.
22. Chang AY, Hui L, Asbury R, et al: Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. Cancer Chemother Pharmacol 1999;44(suppl):26-28.
23. Hill PA, Prince HM, Power DA: Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients. Pathology 2000;32:166-170.
24. Schmidt R, Baumann F, Hanschmann H, et al: Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 2001;26:193-200.
25. Haas R, Schmid H, Hahn U, et al: Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer 1997;33:372-378.
26. Luftner D, Wagner K, Dingeldein G, et al: Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer. Anticancer Res 1999;19:3583-3590.
27. Prince HM, Millward MJ, Rischin D, et al: Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study. Ann Oncol 1999;10:479-481.
28. Schneeweiss A, Hensel M, Goerner R, et al: Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. Stem Cells 2001;19:151-160.
29. Garcia-Rayo S, Perez-Calvo J, Martin-Algarra S, et al: Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: A feasibility study. Bone Marrow Transplant 2001;28:235-242.
30. Perkins JB, Fields KK, Elfenbein GJ: Ifosfamide/carboplatin/etoposide chemotherapy metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: Evaluation of dose-response relationships. Semin Oncol 1995;22:5-8.
31. Kiraz S, Baltali E, Guler N, et al: Ifosfamide and etoposide in previously treated patients with advanced breast cancer. Tumori 1997;83: 604-607.
32. Campisi C, Fabi A, Papaldo P, et al: Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. Ann Oncol 1998; 9:565-567.
33. Aziz Z, Rehman A, Qazi S: Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. Cancer Chemother Pharmacol 1999;44:S9-S12.
34. Murad AM, Guimaraes RC, Amorim WC, et al: Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. Breast Cancer Res Treat 1997;45:47-53.
35. Seo JH, Whang YM, Kim BS, et al: A phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma. Cancer 2002;94:1925-1930.
36. Pronzato P, Queirolo P, Landucci M, et al: Phase II study of vinorelbine and ifosfamide in anthracycline-resistant metastatic breast cancer. Breast Cancer Res Treat 1997;42:183-186.